Recent Company News

• 11:32 AM ET Oct 12, 2026
  

  Asahi Kasei releases 2026 Integrated Report (¥1585.5000, 0)

• 12:52 PM ET Oct 09, 2026
  

  FDA approves Hovilpri (pritelivir) for HSV infection (¥1585.5000, 0)

• 06:53 PM ET Oct 08, 2026
  

  Goldman Sachs downgrades Asahi Kasei & Mitsui Chemicals

• 08:34 AM ET Oct 08, 2026
  

  Asahi Kasei Therapeutics' first patient dosed in Phase 2a Trial of AIC468 for BK Virus infection in kidney transplant recipients (¥1650.5000, 0)

• 01:12 AM ET Oct 08, 2026
  

  Asahi Kasei reports September value of monthly home orders (9%) y/y (¥1656.0000, -8)

• 09:05 PM ET Sep 30, 2026
  

  Teijin Frontier completes business integration with Asahi Kasei Advance

• 07:59 PM ET Sep 29, 2026
  

  Japan August retail sales +2.7% y/y, seasonally-adjusted retail sales (1.2)% m/m

• 08:42 AM ET Sep 29, 2026
  

  Asahi Kasei to integrate Asahi Kasei Therapeutics, Veloxis Pharmaceuticals, Calliditas Therapeutics and AiCuris Anti-infective Cures under Asahi Kasei Therapeutics (¥1611.5000, 0)

• 12:59 PM ET Sep 25, 2026
  

  Asahi Kasei's Zoll Medical awarded max $62.2M Defense Logistics Agency contract modification (yesterday, post-close) (¥1645.5000, 0)

• 11:32 PM ET Sep 24, 2026
  

  Asahi Kasei president Koshiro Kudo says operating income for this FY is on track to be close to ¥270B - Nikkei (pre-Japan open) (¥1643.5000, +37)